The study is designed to evaluate the impact of two different sources of allogeneic progenitor cells on the incidence and severity of chronic graft versus host disease (GVHD) following sibling allogeneic progenitor cell transplantation. Eligible patients will be randomized to receive either G-CSF mobilized allogeneic peripheral blood (G-PB)(standard arm) or G-CSF stimulated allogeneic bone marrow (G-BM) (experimental arm). The study will test the hypothesis that use of G-BM is associated with a longer time to treatment failure (extensive chronic GVHD, relapse, death) than is the use of G-PB for adult allogeneic transplantation for hematologic malignancies. The study will also assess the impact of this novel source of allogeneic progenitor cells on overall survival, disease-free survival, hematologic recovery, secondary outcomes related to hematologic recovery, acute GVHD, overall chronic GVHD, health-related quality of life and economic impact in donors and recipients.